Lexicon Pharmaceuticals Stock Fundamentals
| LXRX Stock | USD 0.37 0.01 2.78% |
Lexicon Pharmaceuticals fundamentals help investors to digest information that contributes to Lexicon Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Lexicon Stock. The fundamental analysis module provides a way to measure Lexicon Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lexicon Pharmaceuticals stock.
At this time, Lexicon Pharmaceuticals' Interest Expense is fairly stable compared to the past year. Total Revenue is likely to rise to about 45.7 M in 2025, whereas Depreciation And Amortization is likely to drop slightly above 507.3 K in 2025. Lexicon | Select Account or Indicator |
Lexicon Pharmaceuticals Company Return On Asset Analysis
Lexicon Pharmaceuticals' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Lexicon Pharmaceuticals Return On Asset | -0.44 |
Most of Lexicon Pharmaceuticals' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lexicon Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Lexicon Total Assets
Total Assets |
|
Based on the latest financial disclosure, Lexicon Pharmaceuticals has a Return On Asset of -0.4377. This is 95.0% lower than that of the Biotechnology sector and 98.15% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Lexicon Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lexicon Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Lexicon Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lexicon Pharmaceuticals competition to find correlations between indicators driving Lexicon Pharmaceuticals's intrinsic value. More Info.Lexicon Pharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Lexicon Pharmaceuticals' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lexicon Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Lexicon Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lexicon Pharmaceuticals' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lexicon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Lexicon Pharmaceuticals by comparing valuation metrics of similar companies.Lexicon Pharmaceuticals is currently under evaluation in return on asset category among its peers.
Lexicon Fundamentals
| Return On Equity | -1.68 | ||||
| Return On Asset | -0.44 | ||||
| Operating Margin | (0.77) % | ||||
| Current Valuation | 3.87 M | ||||
| Shares Outstanding | 361.49 M | ||||
| Shares Owned By Insiders | 1.19 % | ||||
| Shares Owned By Institutions | 84.10 % | ||||
| Number Of Shares Shorted | 44.74 M | ||||
| Price To Earning | 21.02 X | ||||
| Price To Book | 0.91 X | ||||
| Price To Sales | 4.26 X | ||||
| Revenue | 31.08 M | ||||
| Gross Profit | (52.91 M) | ||||
| EBITDA | (184.29 M) | ||||
| Net Income | (200.4 M) | ||||
| Cash And Equivalents | 61.97 M | ||||
| Cash Per Share | 0.34 X | ||||
| Total Debt | 108.4 M | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 3.85 X | ||||
| Book Value Per Share | 0.40 X | ||||
| Cash Flow From Operations | (178.78 M) | ||||
| Short Ratio | 11.94 X | ||||
| Earnings Per Share | (0.63) X | ||||
| Price To Earnings To Growth | (0.14) X | ||||
| Target Price | 2.6 | ||||
| Number Of Employees | 103 | ||||
| Beta | 1.05 | ||||
| Market Capitalization | 132.49 M | ||||
| Total Asset | 298.42 M | ||||
| Retained Earnings | (1.97 B) | ||||
| Working Capital | 200.94 M | ||||
| Current Asset | 171.5 M | ||||
| Current Liabilities | 31.77 M | ||||
| Net Asset | 298.42 M |
About Lexicon Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lexicon Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexicon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexicon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 32.4 M | 20 M | |
| Total Revenue | 31.1 M | 45.7 M | |
| Cost Of Revenue | 616 K | 585.2 K | |
| Stock Based Compensation To Revenue | 0.43 | 0.41 | |
| Sales General And Administrative To Revenue | 311.33 | 326.90 | |
| Research And Ddevelopement To Revenue | 2.72 | 2.58 | |
| Capex To Revenue | 0.03 | 0.03 | |
| Revenue Per Share | 0.10 | 0.09 | |
| Ebit Per Revenue | (6.34) | (6.66) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lexicon Stock Analysis
When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.